Ubs Asset Management Americas Inc Provention Bio, Inc. Transaction History

Ubs Asset Management Americas Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $323,469 - $1.17 Million	48,279 Added 70.95%	116,324 $2.8 Million
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $173,247 - $405,137	38,329 Added 128.98%	68,045 $719,000
Q3 2022 Nov 14, 2022	SELL	$3.43 - $5.62 $75,923 - $124,398	-22,135 Reduced 42.69%	29,716 $133,000
Q2 2022 Aug 12, 2022	BUY	$3.65 - $7.3 $660 - $1,321	181 Added 0.35%	51,851 $207,000
Q1 2022 May 16, 2022	BUY	$3.4 - $7.88 $3,563 - $8,258	1,048 Added 2.07%	51,670 $378,000
Q4 2021 Feb 14, 2022	BUY	$5.59 - $7.39 $58,197 - $76,937	10,411 Added 25.89%	50,622 $284,000
Q3 2021 Nov 15, 2021	BUY	$5.66 - $8.33 $2,892 - $4,256	511 Added 1.29%	40,211 $257,000
Q2 2021 Aug 16, 2021	BUY	$6.71 - $11.04 $83,204 - $136,896	12,400 Added 45.42%	39,700 $334,000
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $213,213 - $464,100	27,300 New	27,300 $385,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.